An early and short gonadotropin releasing hormone (GnRH) antagonist (sandwich) protocol versus conventional gonadotropin releasing hormone (GnRH) antagonist in poor responders undergoing IVF/ICSI

Abstract

In the field of IVF, the term ‘poor responder’ refers to the patients, with decreased ovarian reserve, that revealed as low retrieved oocytes in controlled ovarian hyperstimulation (COH) cycles which is a huge challenge in IVF. This study compares the effectiveness of an early and short gonadotropin releasing hormone (GnRH) antagonist (sandwich) protocol with conventional (GnRH) antagonist in poor ovarian responders. This randomized clinical trial consisted of 61 poor ovarian responder women enrolled in intra-cytoplasmic sperm injection (ICSI) cycles at High Institute for infertility Diagnosis and Assisted Reproductive Technologies, Baghdad, Iraq from January 2018 till February 2019. They were divided randomly in to two groups which are an early and short gonadotropin releasing hormone (GnRH) antagonist (sandwich) protocol group and conventional gonadotropin releasing hormone (GnRH) antagonist protocol group in order to compare between the two groups in the outcomes. The mean number of retrieved oocytes was significantly higher in sandwich than in conventional antagonist protocol (P = 0.026). Mean grade 1 embryo was significantly higher in sandwich protocol than in conventional protocol (P = 0.049). The rate of pregnancy was significantly higher in sandwich than that of conventional antagonist protocol (P = 0.026).
Conclusion: An early GnRH antagonist (sandwich) protocol can improve ovarian response in poor responders by stimulating and synchronizing follicle development

References

  • Alpha Scientist in Reproductive Medicine and ESHRE Special Interest Group of Embryology (2011): The Istanbul consensus workshop on embryo assessment: proceeding of an expert meeting, Human Reproduction. 26(6), pp: 1270–1283.
  • Ashrafi M, Arabipoor A, Yahyaei A, Zolfaghari Z and Ghaffari F. (2018): Does the “delayed start” protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial. Reproductive Biology and Endocrinology.16, p:124.
  • Blockeel C and Devroey P. (2012): Optimisation of the follicular phase in IVF/ICSI. Facts Views Vision in Obgyn.4, pp:203-212.
  • Blockeel C, Riva A, De Vos M, Haentjens P and Devroey P. (2011): Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm injection treatment cycle: impact on ovarian stimulation. A pilot study. Fertility and Sterility.95(5), pp:1714–1719.
  • Cakmak H, Tran N, Zamah A, Cedars M and Rosen M (2014): A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders. Fertility and Sterility.101 (5), pp: 1308–1314.
  • Cédrin-Durnerin I, Guivarc’h-Levêque A, and Hugues J (2012): Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial. Fertility and Sterility.97(6), pp:1359–1364.
  • Davar R, Neghab N, and Naghshineh E (2018):Pregnancy outcome in delayed start antagonist versus microdose flare GnRH agonist protocol in poor responders undergoing IVF/ICSI: An RCT. International Journal of Reproductive Medicin(Yazd).16 (4).pp:255-260.
  • Davar R, Rahsepar M, Rahmani E. A comparative study of luteal estradiol pre-treatment in GnRH antagonist protocols and in micro dose flare protocols for poor-responding patients. Arch Gynecol Obstet. 2013;287:149–153.
  • Ferraretti A, La Marca A, Fauser B, Tarlatzis B, Nargund G, Gianaroli L. (2011): ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reproduction. 26(7), pp:1616–1624.
  • Lee H, Choi H, Yang K, Kim M, Cha S and Yi H. (2018): Efficacy of luteal estrogen administration and an early follicular Gonadotropin-releasing hormone antagonist priming protocol in poor responders undergoing in vitro fertilization. Obstetrics and Gynecology Science. 61(1), pp: 102-110.
  • Mutlu M, Mutlu I, Erdem M, Guler I and Erdem A. (2017): Comparison of the standard GnRH antagonist protocol and the luteal phase estradiol/GnRH antagonist priming protocol in poor ovarian responders. Turkish Journal of Medical Science. 47(2), pp: 470-475.
  • Park C, Hwang Y, Koo H, Kang I, Yang K and Song I. (2014): Early gonadotropin-releasing hormone antagonist start improves follicular synchronization and pregnancy outcome as compared to the conventional antagonist protocol. Clinical and Experimental Reproductive Medicine. 41(4), pp:158-164.
  • Shin J , Park K, Choi Y, Kim H, Choi D, Lee W and Cho J.(2018): Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: A preliminary randomized trial. Clinical and Experimental Reproductive Medicine. 45(3), pp: 135–142.
  • Yang P, Dong X, Wang Y, Wu R, Zhang H and Huang X. (2016): Larger leading follicle size on GnRH antagonist initiation day is associated with higher pregnancy rate in a flexible protocol for IVF/ICSI patients. International Journal of Clinical and Experimental Medicine.9(6), pp:11748-11755.
  • Younis J , Soltsman S, Izhaki I, Radin O, Bar-Ami S, and Ben-Ami M. (2010): Early and short follicular gonadotropin-releasing hormone antagonist supplementation improves the meiotic status and competence of retrieved oocytes in in vitro fertilization–embryo transfer cycles. Fertility and Sterility. 94(4), pp:1350–1355.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.